PGIM India Mutual FundEquity Scheme - Mid Cap Fund12.9 years
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer Axis Midcap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
12.9 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.72% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Watch
Peak-to-trough -36.4%. Ask whether you can hold through a similar fall.
Vs category
Fail
38% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
n/a
Manager not listed.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 21.6% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 36%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
Path not in current snapshots
n/a
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
Path not in current snapshots
n/a
15 Jan 2018 – 6 Aug 2020
Trough 23 Mar 2020 · recovered in 136 days
-36.4%
5 Aug 2015 – 6 Sept 2016
Trough 25 Feb 2016 · recovered in 194 days
-23.7%
17 Jan 2022 – 7 Sept 2022
Trough 20 Jun 2022 · recovered in 79 days
-19.5%
23 Sept 2024 – 16 Sept 2025
Trough 28 Feb 2025 · recovered in 200 days
-19.1%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
29
Vs category
32
Consistency
36
Risk-adjusted
59
Drawdown
9
Mean
33
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 104 holdings · top 10 are 21.6%.
The Federal Bank Ltd
Financial
2.6%
Mankind Pharma Ltd.
Healthcare
2.5%
Aditya Birla Capital Ltd
Financial
2.3%
Bharti Hexacom Ltd.
Technology
2.3%
AU Small Finance Bank Ltd
Financial
2.1%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
27 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
26 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
23 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
21 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
19 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
16 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
24 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
23 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
21 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
18 Sept 2026
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Axis Mutual Fund
Caveat: Higher TER
Baroda BNP Paribas Mutual Fund
Caveat: Higher TER
DSP Mutual Fund
Caveat: Higher TER
ITI Mutual Fund
Caveat: Higher TER
LIC Mutual Fund
Caveat: Higher TER
PGIM India Mutual FundEquity Scheme - Mid Cap Fund12.9 years
Buying brief
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
In three lines
Fits if · Risk-adjusted return sits above the documented risk-free proxy.
Prefer peers if · Prefer Axis Midcap Fund if you want a same-category peer with stronger evidence.
Buy checklist
History depth
Pass
12.9 years of path to read.
Engine status
Watch
Recent evidence is mixed. Compare peers before increasing exposure.
Expense ratio
Pass
0.72% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Watch
Peak-to-trough -36.4%. Ask whether you can hold through a similar fall.
Vs category
Fail
38% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
n/a
Manager not listed.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Pass
Top 10 holdings ≈ 21.6% of the portfolio.
Same-category peers are preloaded into compare when available.
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 36%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
Monitor is recent mixed evidence - keep the SIP unless the buying brief says prefer peers, then swap with intent.
NAV
30 Oct 2026 · -5.0% over 1Y
72.91
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
SIP XIRR
Equal monthly instalments to latest NAV
Peak to trough from a running NAV high, with the path and recovery episodes.
Drawdown
30 Oct 2026
-7.9%
15 Jan 2018 – 6 Aug 2020
Trough 23 Mar 2020 · recovered in 136 days
-36.4%
5 Aug 2015 – 6 Sept 2016
Trough 25 Feb 2016 · recovered in 194 days
-23.7%
17 Jan 2022 – 7 Sept 2022
Trough 20 Jun 2022 · recovered in 79 days
-19.5%
23 Sept 2024 – 16 Sept 2025
Trough 28 Feb 2025 · recovered in 200 days
-19.1%
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
29
Vs category
32
Consistency
36
Risk-adjusted
59
Drawdown
9
Mean
33
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Buying stance
Watch before adding
Recent evidence is mixed. Compare peers before increasing exposure.
Why this status
Supporting reads
30 Sept 2026 · 104 holdings · top 10 are 21.6%.
The Federal Bank Ltd
Financial
2.6%
Mankind Pharma Ltd.
Healthcare
2.5%
Aditya Birla Capital Ltd
Financial
2.3%
Bharti Hexacom Ltd.
Technology
2.3%
AU Small Finance Bank Ltd
Financial
2.1%
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
27 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
26 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
23 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
21 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
19 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
16 Oct 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
24 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
23 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
22 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
21 Sept 2026
PERFORMANCE
Recent rolling excess versus the category median has deteriorated.
18 Sept 2026